Ketamine for Chronic Pain: What 20 Years of RCTs Show

Ketamine has been used in medicine since the 1960s, primarily as an anesthetic. But over the past two decades, a growing body of evidence has examined whether subanesthetic doses — doses well below what would be used for surgery — can meaningfully reduce chronic non-cancer pain. A 2026 systematic review by Zavaleta-Monestel and colleagues, published in Psychoactives, set out to answer that question by analyzing the accumulated evidence from randomized controlled trials spanning twenty years.

Subanesthetic vs. anesthetic dosing

Understanding the distinction between subanesthetic and anesthetic ketamine dosing is essential context. Anesthetic doses of ketamine typically range from 1 to 2 mg/kg administered intravenously and produce full dissociation and loss of consciousness. Subanesthetic protocols for pain — the focus of this review — generally use 0.1 to 0.5 mg/kg IV infusions, or equivalent doses via oral, intranasal, or subcutaneous routes. At these lower doses, patients remain conscious and the primary pharmacological target shifts from broad NMDA receptor blockade to more selective modulation of glutamate signaling, central sensitization, and descending pain pathways.

This distinction matters because subanesthetic dosing is what makes outpatient ketamine therapy feasible and is the dosing range relevant to both pain and mood applications.

Key findings from 20 years of RCTs

The Zavaleta-Monestel review identified and synthesized data from randomized controlled trials published between the early 2000s and 2025. Several patterns emerged from this body of evidence:

Short-term pain reduction is well-supported. Across multiple trial designs and pain conditions, subanesthetic ketamine consistently produced statistically significant reductions in pain intensity compared to placebo in the short term — typically within hours to days of administration. Effect sizes varied by condition and protocol, but the signal was robust.

Duration of benefit remains a challenge. One of the most consistent findings was that pain relief, while often meaningful, tended to be time-limited. Many studies reported that benefits diminished within days to weeks after a single infusion. Serial infusion protocols showed more sustained effects, but optimal dosing schedules remain poorly defined.

Evidence varies by pain condition. The review examined trials across several chronic non-cancer pain types:

• Neuropathic pain had the strongest evidence base, with multiple well-designed RCTs showing benefit for conditions such as postherpetic neuralgia and diabetic neuropathy.
• Complex regional pain syndrome (CRPS) showed promising results, particularly with multi-day infusion protocols, though sample sizes were generally small.
• Fibromyalgia trials demonstrated mixed results — some patients experienced significant improvement while others showed minimal response, suggesting possible subgroup effects.
• Chronic headache and migraine trials were fewer but showed encouraging preliminary data.
• Chronic low back pain and other musculoskeletal conditions had the most heterogeneous results.

Safety at subanesthetic doses was generally acceptable. Adverse effects were predominantly mild and transient — dizziness, nausea, mild dissociation, and transient blood pressure elevation. Serious adverse events were rare across the reviewed trials.

The dual mechanism: pain and mood

One of the more clinically relevant insights from this body of research is that ketamine's pain-relieving and mood-improving effects likely share common mechanisms. NMDA receptor modulation reduces central sensitization (which drives chronic pain amplification) while simultaneously promoting BDNF release and synaptic plasticity (which underlie antidepressant effects). For the estimated 50 percent of chronic pain patients who also meet criteria for depression, this dual mechanism is particularly relevant.

This connection between pain and mood pathways is something we have explored in depth in the context of comorbid pain and depression. The Zavaleta-Monestel review adds an important layer by focusing specifically on pain outcomes independent of mood — confirming that the analgesic effect is not merely a byproduct of mood improvement.

What this means for patients

If you live with chronic non-cancer pain, this systematic review offers cautious optimism. Twenty years of randomized evidence supports subanesthetic ketamine as a treatment that can meaningfully reduce pain intensity, particularly for neuropathic pain conditions. The evidence also suggests that current protocols may need refinement — finding the right dose, frequency, and route of administration for individual patients remains an active area of research.

At Isha Health, we approach ketamine therapy with the understanding that treatment must be personalized. Our physician-led protocols are designed to optimize both dosing and monitoring, and our published outcomes data reflects the results of this individualized approach.

For those living with chronic pain, the takeaway from this review is not that ketamine is a guaranteed solution — but that the evidence base is now substantial enough to support its consideration as part of a comprehensive pain management strategy, particularly when conventional treatments have fallen short.

Reference: Zavaleta-Monestel E, et al. "Subanesthetic ketamine for chronic non-cancer pain: a systematic review of randomized controlled trials." Psychoactives. 2026.

---

Considering ketamine therapy? Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.